They will have to be updated according to the new European Regulation amending Annex II of REACH
Madrid, 04 December 2020 - Azierta's professionals Marta Rodriguez (Industrial Area Director), Ana María de Castro (Industry Science Manager) and Laura Puente (Senior Toxicology Officer) have reviewed in the last webinar organized by the company the new requirements to be implemented due to the amendment in Annex II of the REACH regulation that will come into force next January 1st.
The European REACH Regulation aims to improve the protection of human health and the environment from the risks that can arise from the manufacture, marketing and use of chemical substances and mixtures.
The Safety Data Sheets (SDS) provide comprehensive information on these substances, on their hazards and, as appropriate, estimate the degree of exposure to which humans and the environment will be subjected.
The safety data sheets are to be updated in accordance with the new Regulation (EU) 2020/878 amending Annex II to Regulation (EC) 1907/2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), which will enter into force on 1 January 2021.
Laboratories could continue to provide safety data sheets that do not comply with the amendment to Annex II until 31 December 2022.
In the webinar a thorough review has been made on the new requirements to be implemented in the SDS related to the inclusion of additional information on nanoforms, endocrine disrupting properties and unique formula identifiers (UFI).
The main challenges facing the chemical industry are related to
- The deadline for the implementation of the new information in the SDS, as the new regulation enters into force on 1 January 2021.
- Despite this new regulation, which is soon to come into force, it may be permitted to provide old SDS until 31 December 2022
- Further experience is required to meet the new requirements of the amendment to Annex II.
In addition to accompanying the health industry's products through all their cycles: scientific, manufacturing, distribution and science to business, it offers health infrastructure and management solutions that contribute to improving health standards globally.
Azierta has offices in Madrid, Barcelona, Paris, Lisbon, Milan and Bogotá, as well as a network of international alliances to offer its products and services in the main markets. A team of more than 100 expert professionals develops projects for more than 500 national and international clients.
For more information:
Pablo Navarro - DIRCOM